Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Kidney disease manifests clinically as elevated albumin excretion rate (AER), impaired glomerular filtration rate (GFR), or both, and is a cause of substantial morbidity and mortality in type 1 diabetes (T1D). The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study tested whether intensive diabetes therapy (INT) aimed at lowering glucose concentrations as close as safely possible to the normal range reduces the risks of kidney disease and other diabetes complications. RESEARCH DESIGN AND METHODS: In the DCCT, 1,441 participants with T1D were randomly assigned to INT or conventional diabetes therapy (CON) for a mean duration of 6.5 years. Subsequently, participants have been followed for 18 years in the ongoing observational EDIC. Standardized longitudinal measurements of AER, estimated GFR, and blood pressure were made throughout the DCCT/EDIC. RESULTS: During the DCCT, INT reduced the risks of incident microalbuminuria (AER ≥40 mg/24 h) and macroalbuminuria (AER ≥300 mg/24 h) by 39% (95% CI 21–52%) and 54% (29–74%), respectively. During EDIC years 1–8, participants previously assigned to DCCT INT continued to experience lower rates of incident microalbuminuria and macroalbuminuria, with risk reductions of 59% (39–73%) and 84% (67–92%), respectively. Beneficial effects of INT on the development of impaired GFR (sustained estimated GFR <60 mL/min/1.73 m2) and hypertension became evident during combined DCCT/EDIC follow-up, with risk reductions of 50% (18–69%) and 20% (6–21%), respectively, compared with CON. CONCLUSIONS: In the DCCT/EDIC, INT resulted in clinically important, durable reductions in the risks of microalbuminuria, macroalbuminuria, impaired GFR, and hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this section, the focus is on CKD attributed to diabetes in adults, which occurs in 20-40% of people with diabetes (1-4).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [189]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while the glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m 2 , the kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/ 1.73 m 2 even with no significant change in glucose (4,29,31,107,123,127,129,130).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Hyperglycemia is a known risk factor for the development and progression of both DPN and CKD.9–12”
From Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 1×
“A large body of evidence demonstrates that hyperglycemia contributes to the damage of target organs, including the kidney (5).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102 · cited 1×
“The Chronic Kidney Disease Epidemiology Collaboration equation was used to estimate GFR from calibrated serum creatinine, age, sex, and race (13).”
MethodNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832 · cited 2×
“The DCCT enrolled 1,441 people with T1D from 1983–1989 to determine the effects of INT on the long-term complications of diabetes (7,9).”
BackgroundMethod(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067 · cited 1×
“In early cohort studies, up to 40% of patients with T1D developed macroalbuminuria (AER $300 mg/24 h), and up to 75% of these patients progressed to end-stage renal disease (ESRD) within 10 years (1,2).”
BackgroundIntensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa022314 · Cited by 815
Cited by
Items 201–252 of 252
Rai, B., Pande, A., & Tiwari, S. (2023) · MicroRNA · doi:10.2174/2211536612666230407093841 · Cited by 1
Romeo, G. R., Bennetti, M., VOTTA, J. L., Gibson, C., Gatti, S., & Toschi, E. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.005 · Cited by 3
Diabetespatienten mit chronischer Niereninsuffizienz: Neue Aspekte in Diagnostik und Therapie
Pommer, W., & Oser, B. (2015) · Der Nephrologe · doi:10.1007/s11560-014-0974-x · Cited by 1
Self-Care of Diabetic Nephropathy
Shin, U. J. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.3.176 · Cited by 1
(2018) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2018/7.5.4446 · Cited by 1
Stanton, R. C. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_2 · Cited by 2
Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1409-7
Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1339-4
Gunaid, A. A. (2018) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551417749217 · Cited by 2
Krentowska, A., & Adamska, A. (2015) · Clinical Diabetology · doi:10.5603/dk.2015.0023
An Overview on Diabetic Nephropathy
Fukami, K., & Yamagishi, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00010-6
POTENTIALS TO PREDICT THE DEVELOPMENT OF DIABETES 1 TYPE COMPLICATIONS BY GLUCOSE CONTROL INDICATORS
Перцева, Н. О., & Moshenets, K. I. (2019) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.18.4.41
Rayner, H. C., Thomas, M. E., & Milford, D. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-43027-6_6
Gach, O., & Piérard, L. (2021) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2020.1870194
“Diabetic nephropathy develops in approximately 40% of type-2 diabetic patients and its prevalence increase progressively with the duration of the disease [25].”
BackgroundTactics to prevent or slow progression of CKD in patients with diabetes
Ahmad (2021) · The Journal of Family Practice · doi:10.12788/jfp.0126
New Trends: Time in Range and the Use of Continuous Glucose Monitoring Devices on Glycemic Control
Souza, K. L. V. D., Rassi, M. M. B., de Sá, D. A. R., Bussuan, R. M., Rodrigues, L. C. D. S., & Arbex, A. K. (2021) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2021.3.1.491 · Cited by 1
Peytam, F., Takalloobanafshi, G., Saadattalab, T., Emamgholipour, Z., Norouzbahari, M., Moghimi, S., Firoozpour, L., Bijanzadeh, H. R., Faramarzi, M. A., Mojtabavi, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-144397/v1
Fernández-Fernández, L., Goujat-Salas, J., Ceballos-Malagón, C., Mas, M. T., Caballero, F. L. P., & Buitrago, F. (2021) · Nefrología · doi:10.1016/j.nefro.2021.04.021 · Cited by 7
Diabetes and Kidney Disease: A Review of the Clinical Practice Guidelines
Aggarwal, N., Ali, S., & Navaneethan, S. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_2
Plummer, E. S. (2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch06
Gnecco-González, S., Amaya-Montoya, M., Herrera-Parra, L. J., Vargas, J. A. H., Ramírez-García, N., Romero-Díaz, C., Acuña-Merchán, L. A., & Mendivil, C. O. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac193 · Cited by 1
EARLY MARKERS OF DIABETIC NEPHROPATHY IN CHILDREN WITH TYPE 1 DIABETES MELLITUS
Ahmadov, G. (2022) · World of Medicine and Biology · doi:10.26724/2079-8334-2022-3-81-13-17
Anderzén, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180750325
Fernández-Fernández, L., Goujat-Salas, J., Ceballos-Malagón, C., Mas, M. T., Caballero, F. L. P., & Buitrago, F. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.02.005
Sun, Y., Zhang, Z., Sun, W., Jin, D., An, X., Zhang, Y., Yang, C., Zhang, Y., Duan, Y., Kang, X., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4455400
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults
Plattner, C., Pirklbauer, M., & Mayer, G. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2244420
“In this regard, prolonged periods of poor glucose control negatively affect renal prognosis, a phenomenon known as ‘legacy effect’ [15].”
BackgroundGómez, M. I. (2023) · JOJ Urology & Nephrology · doi:10.19080/jojun.2023.08.555735
Non-streptococcal Bacteria as the Leading Cause of Infection-related Glomerulonephritis in Adults
Gómez, M. I. (2023) · JOJ Urology & Nephrology · doi:10.19080/jojun.2023.08.555736 · Cited by 1
Carnosine and Carnosinase 1 in Diabetic Kidney Disease
Qiu, J. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.819384487
Prevention and management of chronic kidney disease in diabetes
Barlovič, D. P., & Groop, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00004-x
Renal Reinforcements: Slowing Diabetic Kidney Disease with Multiple New Agents
Thomas, R. L., & Rifkin, D. E. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000458
Diabetic Nephropathy and End-Stage Renal Disease
Childs, B. P. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch13
Microvascular complications of diabetes - their prevention and treatment
Lášticová, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.079
Association of miRNA451a with Insulin Resistance and Diabetes Kidney Disease
张, 芷. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14112955
Do You Have Diabetes Mellitus?: How Diabetes and Its Treatments Are Linked to Kidney Disease
Rayner, H. C., Thomas, M. E., Dasgupta, I., Lalayiannis, A. D., & Hameed, M. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66349-9_7
Pharmacotherapy of type 1 diabetes - part 1: yesterday
Rendell, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2454280
Nie, Y., Yu, H., Wan, X., Lü, Z., Cao, S., Yang, D., & Xiao, D. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144063
RetractedDiabetic Kidney Disease: A Versatile Disease
Granados‐Silvestre, M. D. L. Á., Ortiz‐López, M. G., & Sanchez-Pozos, K. A. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305692125010013
Fang, Y., Jing, L., Zhu, Y., Wang, H., Xia, J., Lei, T., Lu, J., & Gao, J. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109162 · Cited by 2
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Diabetespatienten mit chronischer Niereninsuffizienz: Neue Aspekte in Diagnostik und Therapie
Pommer, W., & Oser, B. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1274-9
Folgeerkrankungen und Prognose des Typ-1-Diabetes
Danne, T., Kordonouri, O., & Lange, K. (2014) · Springer eBooks · doi:10.1007/978-3-642-24645-6_7 · Cited by 1
ЧАСТОТА И ФАКТОРЫ РИСКА ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ У ДЕТЕЙ С САХАРНЫМ ДИАБЕТОМ 1 ТИПА
Шевцова, Н. О., & Шламова, М. О. (2025) · Смоленский медицинский альманах · doi:10.37903/sma.2025.2.62
XiaoLong, W., Jian, Y., Liang, S., & Dong, Z. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag097 · Cited by 1
Ngaba, N. N., Lovallo, V., ONeil, A., Quidet, X., Asare, M., Nabeta, H., Thakur, S., Agyemang, R. O., Alataa, R. F., Hocine, F. K., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1755934
“According to large-scale studies (21, 22), in patients with diabetes (which includes MODY), it takes approximately 10–20 years for the progression to ESRD from microalbuminuria, but it can be earlier in some cases, depending on glycemic control and other risk factors (HTN, lifestyle, and adherence).”
Ran, X., Xu, Y., 梁, 若., Duan, Y., Jia, W., Bian, Y., Li, C., & Zhang, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114801
“…the concept of “metabolic memory” has been established based on a range of clinical and experimental studies, which describes the persistent molecular damage caused by prior hyperglycemic exposure that continues to drive disease progression even after subsequent glycemic normalization [11,12].”
Genetic Risk Factors for Kidney Function in Individuals with Type 1 Diabetes
Limonte, C. P., Gao, X., Roshandel, D., Bebu, I., Karger, A. B., Lorenzi, G. M., de Boer, I. H., Perkins, B. A., & Paterson, A. D. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001111 · Cited by 1
Paediatric Diabetic Kidney Disease: Screening, Signs, and Strategies
Milyani, A. A., Alsubaie, H., Bahadori, A., Patel, R., & Selvathesan, N. (2026) · Current Pediatrics Reports · doi:10.1007/s40124-026-00382-0
“Partici ‑ pants were subsequently enrolled in the Epidemiology of Diabetes Interventions and Complications (EDIC) cohort where they were longitudinally followed for 18 years with evidence of sustained risk reduction for incident albumin ‑ uria, GFR decline, and hypertension [ 59].”
Shikata, K., Miyamoto, S., Haneda, M., Hosoi, H., Sakamoto, K., Suzuki, Y., Suzuki, D., Ishida, H., Akai, H., Tomino, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70392
Ansari, M. D., Vishwakarma, A., Quamuddin, M., Aggarwal, M., Khan, H., Jalil, M. F. A., Mahmood, S., Wali, A. F., Talath, S., & El-Tanani, M. (2026) · Frontiers in Medical Technology · doi:10.3389/fmedt.2026.1951734
“In chronic hyperglycemia, a transient spike in blood glucose may have a long-lasting impact on DN development (120, 121).”
Kitaeva, K. V., Solovyeva, V. V., & Rizvanov, A. A. (2026) · Diseases · doi:10.3390/diseases14100383
Metadata
- Authors
- de Boer, I. H., & for the DCCT/EDIC Research Group
- Affiliations
- Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, WA
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 24-30
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3867994
- OpenAlex
- W2160388935
- Semantic Scholar
- 0e25853fef3a739d11a78c1cdc288086bfda2756
- Cited by
- 254
- References
- 38
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 20 · 2023: 26 · 2022: 28 · 2021: 20 · 2020: 27 · 2019: 21 · 2018: 16 · 2017: 12 · 2016: 16 · 2015: 27 · 2014: 11 · 2013: 3
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, U01DK094176, U01-DK094157, RC4DK090766, R01DK088762, P30DK017047)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, diabetic nephropathy, urinary albumin excretion rate, microalbuminuria, macroalbuminuria, glomerular filtration rate, intensive diabetes therapy, glycemic control, hypertension, DCCT/EDIC
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypertension, Insulin, Kidney, Male, Middle Aged, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.